[1]张宏岩,任俊杰,赵振兴,等.晚期NSCLC患者α/β水解酶折叠蛋白5和细胞免疫指标水平表达与替雷利珠单抗靶向治疗应答的关系研究[J].现代检验医学杂志,2025,40(04):8-12,23.[doi:10.3969/j.issn.1671-7414.2025.04.002]
　ZHANG Hongyan,REN Junjie,ZHAO Zhenxing,et al.Relationship between ABHD5 and Cellular Immune Indexes and Response to Tirelizumab Targeted Therapy in Patients with Advanced NSCLC[J].Journal of Modern Laboratory Medicine,2025,40(04):8-12,23.[doi:10.3969/j.issn.1671-7414.2025.04.002]
点击复制

晚期NSCLC患者α/β水解酶折叠蛋白5和细胞免疫指标水平表达与替雷利珠单抗靶向治疗应答的关系研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年04期
页码:
8-12,23
栏目:
论著
出版日期:
2025-07-15

文章信息/Info

Title:
Relationship between ABHD5 and Cellular Immune Indexes and Response to Tirelizumab Targeted Therapy in Patients with Advanced NSCLC
文章编号:
1671-7414（2025）04-008-06
作者:
张宏岩1，任俊杰1，赵振兴1，王现雷1,2
（1. 开滦总医院心胸外科，河北唐山 063000；2. 苏州大学附属第二医院，江苏苏州 215004）
Author(s):
ZHANG Hongyan1，REN Junjie1，ZHAO Zhenxing1，WANG Xianlei1,2
(1. Department of Cardiothoracic Surgery，Kailuan General Hospital，Hebei Tangshan 063000，China；2. the Second Affiliated Hospital of Soochow University，Jiangsu Suzhou 215004，China)
关键词:
α/β 水解酶折叠蛋白5; 细胞免疫; 替雷利珠单抗; 晚期非小细胞肺癌; 免疫应答
分类号:
R734.2；R730.43；
DOI:
10.3969/j.issn.1671-7414.2025.04.002
文献标志码:
A
摘要:
目的 探究α/β 水解酶折叠蛋白5（ABHD5）和细胞免疫指标水平表达对晚期非小细胞肺癌（NSCLC）患者替雷利珠单抗靶向治疗应答的影响。方法 选择2020 年10 月～ 2023 年12 月在开滦总医院就诊并接受替雷利珠单抗治疗的123 例晚期NSCLC 患者，治疗4 周后评价目标病灶疗效，并根据治疗效果分为应答组和无应答组。实时定量聚合酶链反应（RT-qPCR）检测病灶组织中ABHD5 相对表达。比较两组ABHD5 表达水平、免疫指标[CD4+T，CD8+T，CD4+T/CD8+T，调节性T 细胞（Treg），辅助性T 细胞17（Th17），Treg/Th17] 及其他临床指标。多因素Logistic 回归分析影响替雷利珠单抗靶向治疗应答的独立因素；受试者工作特征（ROC）曲线分析ABHD5，CD4+T，CD8+T 对晚期NSCLC 治疗不应答的预测价值；Pearson 相关性分析ABHD5 表达与CD4+T，CD8+T 细胞的相关性。结果 入组123 例患者治疗应答90 例，无应答33 例。无应答组ABHD5 表达（1.16±0.18）及CD4+T（31.52%±4.26%），CD8+T（24.39%±1.87%）细胞水平低于应答组（1.47±0.21，36.43%±4.08%，29.13%±2.15%），Treg（7.24%±0.89%）和Th17（6.23%±1.10%）细胞水平高于应答组（6.37%±0.91%，5.42%±0.66%），差异具有统计学意义（t=4.725 ～ 11.200，均P ＜ 0.05）。两组肿瘤大小、转移数量、癌胚抗原（CEA）、白蛋白（Alb）、总胆红素（TBIL）水平比较，差异具有统计学意义（t=2.969 ～ 6.523，均P ＜ 0.05）。ABHD5 表达及CD4+T，CD8+T 细胞水平是影响晚期NSCLC 替雷利珠单抗靶向治疗应答的独立保护因素（Wald χ2=15.803，7.954，8.631，均P ＜ 0.05）。ABHD5 预测晚期NSCLC 治疗不应答的AUC 为0.897，高于CD4+T 和CD8+T 细胞预测的0.860 和0.835，其预测敏感度、特异度分别为72.73% 和94.45%。ABHD5 表达与CD4+T，CD8+T 细胞水平呈正相关（r=0.367，0.355，均P ＜ 0.05）。结论 晚期NSCLC 替雷利珠单抗靶向治疗应答与ABHD5 表达和CD4+T，CD8+T 细胞水平显著相关，且ABHD5 对晚期NSCLC 治疗疗效具有较高的预测价值。
Abstract:
Objective To investigate the effect of α/β hydrolase folded protein 5 (ABHD5) and cellular immunity markers on the response to tirellizumab targeted therapy in patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 123 patients with advanced NSCLC who received tiralizumab in Kailuan General Hospital from October 2020 to December 2023 were selected. The efficacy of the target lesions was evaluated 4 weeks after treatment, and the patients were divided into response group and non-response group according to the treatment effect. Quantitative real time polymerase chain reaction (RTqPCR) was used to detect the relative expression of ABHD5 in lesion tissues. The expression level of ABHD5, immune indexes [CD4+T, CD8+T, CD4+T/CD8+T, regulatory T cell (Treg), T helper cell 17 (Th17), Treg/Th17] and other clinical indexes were compared between the two groups. Multivariate logistic regression analysis of independent factors influencing response to tirelizumab targeted therapy. The predictive value of ABHD5, CD4+T and CD8+T in non-response to treatment of advanced NSCLC was analyzed by receiver operating characteristic (ROC). ABHD5 expression was correlated with CD4+T and CD8+T cells by Pearson correlation analysis. Results Among the 123 patients enrolled, 90 responded to treatment and 33 did not respond.The expression of ABHD5 (1.16±0.18) and the levels of CD4+T(31.52%±4.26%) and CD8+T(24.39%±1.87%) cells in the non-response group were lower than those in the response group（1.47±0.21，36.43%±4.08%，29.13%±2.15%）, and the levels of Treg(7.24%±0.89%) and Th17(6.23%±1.10%） cells were higher than those in the response group（6.37%±0.91%， 5.42%±0.66%）, and the differences were statistically significant (t=4.725 ～ 11.200, all P<0.05). There were significant differences in tumor size, number of metastases and levels of carcinoembryonic antigen (CEA), albumin (ALB) and total bilirubin (TBIL) between the two groups，and the differences were statistically significant (t=2.969 ～ 6.523，all P<0.05). ABHD5 expression and CD4+T, CD8+T cell levels were independent protective factors affecting the response to tirelizumab targeted therapy in advanced NSCLC (Wald χ2=15.803，7.954，8.631，all P < 0.05). ABHD5 predicted that the AUC of non-response to treatment of advanced NSCLC was 0.897, which was higher than that of 0.860 and 0.835 predicted by CD4+T and CD8+T cells, and the prediction sensitivity and specificity were 72.73% and 94.45%, respectively. ABHD5 expression was positively correlated with the levels of CD4+T and CD8+T cells (r=0.367, 0.355，all P<0.05). Conclusion The response to tirelizumab targeted therapy in advanced NSCLC is significantly correlated with the expression of ABHD5 and the levels of CD4+T and CD8+T cells, and ABHD5 has high predictive value in the treatment of advanced NSCLC.

参考文献/References:

[1] WU Y L, ZHANG L, FAN Y, et al. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer:KEYNOTE-042 China study[J]. International Journal of Cancer, 2021, 148(9): 2313-2320.
[2] 王旋, 崔立春, 党升强. 非小细胞肺癌放化疗联合靶向治疗对血清肿瘤标志物、 免疫功能及CyclinD3 水平影响的相关研究[J]. 现代检验医学杂志,2021,36(4):25-30. WANG X, CUI L C, DANG S Q. Effects of radiotherapy and chemotherapy combined with targeted therapy on serum tumor markers, immune function and CyclinD3 level in non-small cell lung cancer[J]. Journal of Modern Laboratory Medicine, 2021, 36(4): 25-30.
[3] 杨亚冰, 田丰. 小细胞肺癌的靶向治疗与免疫治疗的研究进展[J]. 癌症进展,2020,18(14):1424-1426. YANG Y B, TIAN F. Research progress of targeted therapy and immunotherapy for small cell lung cancer[J]. Oncology Progress, 2020, 18(14): 1424-1426.
[4] TSENG Y Y, SANDERS M A, ZHANG H M, et al. Structural and functional insights into ABHD5,a ligand-regulated lipase co-activator[J]. Scientific Reports, 2022, 12(1): 2565.
[5] 姚露岩, 王子安.CD68 与ABHD5 在胃癌组织中的表达及临床意义[J]. 国际肿瘤学杂志,2018,45(3):153-156. YAO L Y, WANG Z A. Expressions and clinical significances of CD68 and ABHD5 in gastric carcinoma[J]. Journal of International Oncology, 2018,45(3): 153-156.
[6] SHANG S L, JI X R, ZHANG L L, et al. Macrophage ABHD5 suppresses NFκB-dependent matrix metalloproteinase expression and cancer metastasis[J]. Cancer Research, 2019, 79(21): 5513-5526.
[7] ZENG Z, YU J C, YANG Z, et al. Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer:evidence from bioinformatic and experiments [J]. Frontiers in oncology, 2022, 12: 1096449.
[8] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. European Journal of Cancer, 2009, 45(2): 228-247.
[9] 王韵涵, 郑晓丽, 孙亚楠, 等. 肺免疫预后指数与局部晚期非小细胞肺癌放化疗预后的关系[J]. 中华放射医学与防护杂志,2022,42(7):504-510. WANG Y H, ZHENG X L, SUN Y N, et al. Relationship between lung immune prognostic and the prognosis of locally advanced non-small cell lung cancer treated with radiochemotherapy[J]. Chinese Journal of Radiological Medicine and protection, 2022, 42(7):504-510.
[10] 赵梅, 张以若, 杜瀛瀛.ALK 融合基因阳性的非小细胞肺癌靶向治疗进展[J]. 中华全科医学,2020,18(2):286-290. ZHAO M, ZHANG Y R, DU Y Y. Targeted treatment of ALK-rearranged advanced NSCLC[J]. Chinese Journal of General Practice, 2020, 18(2): 286-290.
[11] WANG J, LU S, YU X M, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial[J]. JAMA Oncology, 2021, 7(5): 709-717.
[12] LIU S Y, WU Y L. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced nonsmall cell lung cancer (NSCLC)[J]. Expert Opinion on Investigational Drugs, 2020, 29(12): 1355-1364.
[13] YANG A, MOTTILLO E P. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics[J]. Biochemical Journal, 2020, 477(5): 985-1008.
[14] CHEN G H, ZHOU G L, LOTVOLA A, et al. ABHD5 suppresses cancer cell anabolism through lipolysisdependent activation of the AMPK/mTORC1 pathway[J]. Journal of Biological Chemistry, 2021,296: 100104.
[15] PHILIP M, SCHIETINGER A. CD8+T cell differentiation and dysfunction in cancer[J]. Nature Reviews Immunology, 2022, 22(4): 209-223.
[16] FU L Q, YANG X, CAI M H, et al. Role of Treg/Th17 imbalance, microbiota and miRNAs in pancreatic cancer: therapeutic options[J]. Critical Reviews in Immunology, 2020, 40(1): 75-92.
[17] GU Y, CHEN Y R, WEI L, et al. ABHD5 inhibits YAPinduced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation[J]. Nature Communications, 2021, 12(1): 6711.
[18] ZHOU Q F, SUN Y. Circular RNA cMras suppresses the progression of lung adenocarcinoma through ABHD5/ATGL axis using NF-κB signaling pathway[J]. Cancer Biotherapy and Radiopharmaceuticals, 2023, 38(5):336-346.
[19] FORD K, HANLEY C J, MELLONE M, et al. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8+ T-cell exclusion from tumors[J]. Cancer Research, 2020,80(9): 1846-1860.

相似文献/References:

[1]康晓嫒,周川平.儿童难治性支原体肺炎患者细胞免疫和体液免疫指标检测价值分析[J].现代检验医学杂志,2019,34(06):138.[doi:10.3969 ／ j.issn.1671-7414.2019.06.035]
　KANG Xiao-yuan,ZHOU Chuan-ping.Detection Value of Cellular Immunity and Humoral Immunity in Children with Refractory Mycoplasmal Pneumonia[J].Journal of Modern Laboratory Medicine,2019,34(04):138.[doi:10.3969 ／ j.issn.1671-7414.2019.06.035]
[2]李涤蓉,赵 蓉,石亚玲,等.疟疾患者外周血T 淋巴细胞亚群检测及临床意义[J].现代检验医学杂志,2023,38(02):186.[doi:10.3969/j.issn.1671-7414.2023.02.035 ]
　Department of Clinical Laboratory,the Eighth Peoples Hospital of Guangzhou Medical University,Guangzhou000,et al.LI Di-rong, ZHAO Rong, SHI Ya-ling ,LIU Yan-xia, JIANG Hong-ya, FAN Ying-min[J].Journal of Modern Laboratory Medicine,2023,38(04):186.[doi:10.3969/j.issn.1671-7414.2023.02.035 ]

备注/Memo

备注/Memo:
基金项目：江苏省卫生健康委科研项目（M2022065）。
作者简介：张宏岩（1986-），男，硕士，主治医师，研究方向：肺部肿瘤、食管肿瘤诊断及治疗，E-mail：ktsr@tmu.edu.cn。
通讯作者：赵振兴（1976-），男，硕士，主任医师，研究方向：肺部肿瘤、食管肿瘤诊断及治疗，E-mail：15373569737@163.com。
更新日期/Last Update: 2025-07-15